NASDAQ: CNSPCns Pharmaceuticals Inc Stock Ownership - Who owns Cns Pharmaceuticals?
Insider buying vs selling
Have Cns Pharmaceuticals Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| John M. Climaco | Chief Executive Officer | 2024-02-01 | 166,666 | $0.30 | $50.00kBuy |
| Christopher Downs | Chief Financial Officer | 2024-02-01 | 66,666 | $0.30 | $20.00kBuy |
| Carl Anthony Evans | Director | 2024-02-01 | 33,333 | $0.30 | $10.00kBuy |
| Jerzy Gumulka | Director | 2024-02-01 | 33,333 | $0.30 | $10.00kBuy |
CNSP insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when CNSP insiders and whales buy or sell their stock.
CNSP Shareholders
What type of owners hold Cns Pharmaceuticals Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Cortice Biosciences Inc | 1.78% | 573,368 | $91.74k | Insider |
| John M. Climaco | 0.67% | 215,676 | $34.51k | Insider |
| Waldemar Priebe | 0.49% | 156,807 | $25.09k | Insider |
| Anson Funds Management LP | 0.44% | 141,398 | $22.62k | Institution |
| Christopher Downs | 0.32% | 103,438 | $16.55k | Insider |
| Jerzy Gumulka | 0.13% | 43,006 | $6.88k | Insider |
| Carl Anthony Evans | 0.10% | 33,458 | $5.35k | Insider |
| Jeffry R. Keyes | 0.03% | 11,100 | $1.78k | Insider |
| Ubs Group Ag | 0.01% | 2,629 | $420.64 | Institution |
| Tower Research Capital LLC Trc | 0.00% | 115 | $18.40 | Institution |
CNSP vs Biotech Stocks
Cns Pharmaceuticals Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.